Sarcopenia. Muscle wasting and atrophy, not elsewhere classified
Conditions
Interventions
Intervention 1: The experimental designed program consisted of 12 weeks of resistance training and four weeks of detraining. Resistance training program was performed three times a week (non-consecuti
Prevention
The experimental designed program consisted of 12 weeks of resistance training and four weeks of detraining. Resistance training program was performed three times a week (non-consecutive session), thr
Sponsors
Research Institute for Endocrine Sciences
Eligibility
Sex/Gender
Female
Age
50 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: post menopausal woman; age over 50 years old. Exclusion Criteria: taking hormone replacement therapy (HRT); use of medications like ß-adrenergic blockers, ß-agonists, Ca2+ channel blockers and corticosteroids; having diabetes, Parkinson’s disease and peripheral neuropathy.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Muscle Weakness. Timepoint: ?At baseline, After 12 weeks, After 16 weeks. Method of measurement: Caliper. | — |
Secondary
| Measure | Time frame |
|---|---|
| Rang of Motion. Timepoint: At baseline, After 12 weeks, After 16 weeks. Method of measurement: Sit and Reach. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contact?Dr. Arash Ganbarian
Research Institute for Endocrine Sciences
Outcome results
None listed